AR003175A1 - Una composicion farmaceutica que comprende un portador farmaceuticamente aceptable y un agente quimioterapeutico y un triazol, dicha composicion farmaceutica , dicha composicion farmaceutica que comprend eun potenciador, uso de un agente quimioterapeutico y un 1h-1,2,4-triazol y uso de un potenciador y dicho triazol para tratar cancer, tumores o infecciones virales en mamiferos de sangre caliente - Google Patents

Una composicion farmaceutica que comprende un portador farmaceuticamente aceptable y un agente quimioterapeutico y un triazol, dicha composicion farmaceutica , dicha composicion farmaceutica que comprend eun potenciador, uso de un agente quimioterapeutico y un 1h-1,2,4-triazol y uso de un potenciador y dicho triazol para tratar cancer, tumores o infecciones virales en mamiferos de sangre caliente

Info

Publication number
AR003175A1
AR003175A1 ARP960103860A AR10386096A AR003175A1 AR 003175 A1 AR003175 A1 AR 003175A1 AR P960103860 A ARP960103860 A AR P960103860A AR 10386096 A AR10386096 A AR 10386096A AR 003175 A1 AR003175 A1 AR 003175A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical composition
potential
triazol
tumors
mammals
Prior art date
Application number
ARP960103860A
Other languages
English (en)
Spanish (es)
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/674,180 external-priority patent/US5908855A/en
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of AR003175A1 publication Critical patent/AR003175A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ARP960103860A 1995-08-04 1996-08-02 Una composicion farmaceutica que comprende un portador farmaceuticamente aceptable y un agente quimioterapeutico y un triazol, dicha composicion farmaceutica , dicha composicion farmaceutica que comprend eun potenciador, uso de un agente quimioterapeutico y un 1h-1,2,4-triazol y uso de un potenciador y dicho triazol para tratar cancer, tumores o infecciones virales en mamiferos de sangre caliente AR003175A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US188995P 1995-08-04 1995-08-04
US08/674,180 US5908855A (en) 1996-07-16 1996-07-16 Compositions for treating viral infections

Publications (1)

Publication Number Publication Date
AR003175A1 true AR003175A1 (es) 1998-07-08

Family

ID=26669622

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP960103860A AR003175A1 (es) 1995-08-04 1996-08-02 Una composicion farmaceutica que comprende un portador farmaceuticamente aceptable y un agente quimioterapeutico y un triazol, dicha composicion farmaceutica , dicha composicion farmaceutica que comprend eun potenciador, uso de un agente quimioterapeutico y un 1h-1,2,4-triazol y uso de un potenciador y dicho triazol para tratar cancer, tumores o infecciones virales en mamiferos de sangre caliente

Country Status (18)

Country Link
EP (1) EP0841921A2 (cs)
JP (1) JPH11510187A (cs)
KR (1) KR19990036138A (cs)
CN (1) CN1195288A (cs)
AR (1) AR003175A1 (cs)
AU (1) AU711966B2 (cs)
BR (1) BR9609966A (cs)
CA (1) CA2229024A1 (cs)
CZ (1) CZ33798A3 (cs)
HU (1) HUP9903420A3 (cs)
IL (1) IL123095A0 (cs)
MX (1) MX9800998A (cs)
NO (1) NO980473L (cs)
NZ (2) NZ315184A (cs)
PL (1) PL324904A1 (cs)
SK (1) SK14198A3 (cs)
TR (2) TR199800270T1 (cs)
WO (1) WO1997005873A2 (cs)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6479526B1 (en) 1995-04-12 2002-11-12 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of viruses and cancers
US6262093B1 (en) 1995-04-12 2001-07-17 The Proctor & Gamble Company Methods of treating cancer with benzimidazoles
US6177460B1 (en) 1995-04-12 2001-01-23 The Procter & Gamble Company Method of treatment for cancer or viral infections
US5770616A (en) 1995-06-07 1998-06-23 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of cancers
US6265427B1 (en) 1995-06-07 2001-07-24 The Proctor & Gamble Company Pharmaceutical composition for the method of treating leukemia
US6686391B2 (en) 1995-08-04 2004-02-03 University Of Arizona Foundation N-chlorophenylcarbamate and N-chlorophenylthiocarbamate compositions
FR2742405B1 (fr) * 1995-12-13 1998-02-27 Cgea Comp Gen Entre Auto Unite motrice susceptible d'etre accouplee a une enceinte roulante et vehicule resultant
US5900429A (en) 1997-01-28 1999-05-04 The Procter & Gamble Company Method for inhibiting the growth of cancers
PE11499A1 (es) * 1997-05-16 1999-03-01 Procter & Gamble Tratamiento del hiv y cancer
US6506783B1 (en) 1997-05-16 2003-01-14 The Procter & Gamble Company Cancer treatments and pharmaceutical compositions therefor
US6245789B1 (en) 1998-05-19 2001-06-12 The Procter & Gamble Company HIV and viral treatment
DK2055313T3 (en) * 1998-11-09 2015-07-27 Biogen Inc Treatment of Hematologic Malignancies Related to Circulating Tumor Cells Using Chimeric Anti-CD20 Antibody
US6423734B1 (en) 1999-08-13 2002-07-23 The Procter & Gamble Company Method of preventing cancer
US6407105B1 (en) 2000-09-26 2002-06-18 The Procter & Gamble Company Compounds and methods for use thereof in the treatment of cancer or viral infections
US6380232B1 (en) 2000-09-26 2002-04-30 The Procter & Gamble Company Benzimidazole urea derivatives, and pharmaceutical compositions and unit dosages thereof
US6462062B1 (en) 2000-09-26 2002-10-08 The Procter & Gamble Company Compounds and methods for use thereof in the treatment of cancer or viral infections
US6608096B1 (en) 2000-09-26 2003-08-19 University Of Arizona Foundation Compounds and methods for use thereof in the treatment of cancer or viral infections
US7004915B2 (en) * 2001-08-24 2006-02-28 Kci Licensing, Inc. Negative pressure assisted tissue treatment system
RU2201230C1 (ru) * 2001-12-24 2003-03-27 Закрытое акционерное общество "Брынцалов-А" Лекарственное средство флузол, обладающее противогрибковым действием
EP1895012A1 (en) 2006-08-30 2008-03-05 Universitätsklinikum Freiburg Method for inducing tumor apoptosis by increasing nitric oxide levels
WO2008073961A2 (en) * 2006-12-12 2008-06-19 Emory University Compounds and methods for modulating the silencing of a polynucleotide of interest
WO2019185521A1 (en) * 2018-03-26 2019-10-03 Westfälische Wilhelms-Universität Münster Ergosterol-biosynthesis inhibitor and influenza virus infection

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0196855A3 (en) * 1985-03-29 1989-04-12 Pfizer Inc. Tioconazole and related compounds for prevention of sexually transmitted diseases and control of herpetic infections
BE1004029A6 (nl) * 1990-11-22 1992-09-08 Mol Omer De Farmaceutische samenstelling en farmaceutische set voor het behandelen van kanker.
US5565478A (en) * 1994-03-14 1996-10-15 The United States Of America As Represented By The Department Of Health & Human Services Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs
US5665751A (en) * 1995-06-07 1997-09-09 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of cancers

Also Published As

Publication number Publication date
IL123095A0 (en) 1998-09-24
NZ503921A (en) 2002-03-01
NO980473L (no) 1998-04-03
CZ33798A3 (cs) 1998-06-17
JPH11510187A (ja) 1999-09-07
WO1997005873A3 (en) 1997-03-27
EP0841921A2 (en) 1998-05-20
KR19990036138A (ko) 1999-05-25
HUP9903420A3 (en) 2001-12-28
TR199800270T1 (xx) 1998-05-21
NO980473D0 (no) 1998-02-03
SK14198A3 (en) 1999-03-12
WO1997005873A2 (en) 1997-02-20
BR9609966A (pt) 1999-02-02
AU6683396A (en) 1997-03-05
TR199801739T2 (xx) 1998-12-21
CN1195288A (zh) 1998-10-07
MX9800998A (es) 1998-04-30
PL324904A1 (en) 1998-06-22
AU711966B2 (en) 1999-10-28
CA2229024A1 (en) 1997-02-20
NZ315184A (en) 2000-05-26
HUP9903420A2 (hu) 2000-03-28

Similar Documents

Publication Publication Date Title
AR003175A1 (es) Una composicion farmaceutica que comprende un portador farmaceuticamente aceptable y un agente quimioterapeutico y un triazol, dicha composicion farmaceutica , dicha composicion farmaceutica que comprend eun potenciador, uso de un agente quimioterapeutico y un 1h-1,2,4-triazol y uso de un potenciador y dicho triazol para tratar cancer, tumores o infecciones virales en mamiferos de sangre caliente
AR003174A1 (es) Una composicion farmaceutica que comprende un portador farmaceuticamente aceptable y un agente quimioterapeutico y un triazol, dicha composicion farmaceutica que comprende un potenciador, uso de un agente quimioterapeutico y un 1h-1,2,4-triazol y uso de un potenciador y dicho triazol para tratar cancer, tumor o infecciones virales en mamiferos de sangre caliente
FR10C0046I1 (cs)
GT199800126A (es) Terapia de combinacion.
MY116478A (en) Tri-substituted imidazoles having multiple therapeutic properties
ID29930A (id) Senyawa-senyawa triazol dan penggunaannya
IE821285L (en) Triazole antifungal agents
KR910021398A (ko) 트리아졸 항진균제
ES2130542T3 (es) Procedimiento para preparar clorhidrato de 1-(2'-desoxi-2',2'-difluoro-d-ribofuranosil)-4-aminopirimidin-2-ona.
TR199801323T2 (xx) 1,2,4-triazol t�revlerinin, vir�tik enfeksiyonlar�n tedavisi i�in bir ila� �retilmesinde kullan�m�.
HUP9802629A3 (en) Use of 1,3-bis(1,2,4-triazolyl)propan-2-ol derivatives for the manufacture of pharmaceutical compositions treating cancers
AR043071A1 (es) Uso de macrolidos para el tratamiento del cancer y degeneracion macular y una composicion farmaceutica
AU8032682A (en) Formulations of known antimycotic azoles
MX9800945A (es) Uso de griseofulvina para inhibir el crecimiento de canceres.
IE831371L (en) 1,2,4-triazole derivatives
ES2129893T3 (es) Dinucleosido-5',5'-pirofosfatos.
ES2116411T3 (es) La sal sulfato de un triazol sustituido, composiciones farmaceuticas de la misma y su uso en terapia
KR920012049A (ko) 불소 화합물
YU13599A (sh) Primena farmaceutske kompozicije za dobijanje leka u obliku gela
BR0017046A (pt) Uso de azóis para prevenção de câncer de pele
ES8503680A1 (es) Un procedimiento para la preparacion de un compuesto dotado de propiedades fungicidas
EP0367069A3 (de) Substituierte Bisazole, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
ES2170377T3 (es) Composicion que contiene quitosana.
ES8704464A1 (es) Un procedimiento para la preparacion de derivados de imidazol.
ES2184289T3 (es) Suministracion de un agente anticanceroso mejorado a tumores solidos como primer componente.

Legal Events

Date Code Title Description
FC Refusal